CN101317605B - 新型功能性奶粉的配制方法 - Google Patents
新型功能性奶粉的配制方法 Download PDFInfo
- Publication number
- CN101317605B CN101317605B CN2007100723227A CN200710072322A CN101317605B CN 101317605 B CN101317605 B CN 101317605B CN 2007100723227 A CN2007100723227 A CN 2007100723227A CN 200710072322 A CN200710072322 A CN 200710072322A CN 101317605 B CN101317605 B CN 101317605B
- Authority
- CN
- China
- Prior art keywords
- weight
- parts
- milk powder
- lentinan
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000843 powder Substances 0.000 title claims abstract description 45
- 235000020604 functional milk Nutrition 0.000 title claims abstract description 16
- 238000000034 method Methods 0.000 title claims description 21
- 229920001491 Lentinan Polymers 0.000 claims abstract description 17
- 229940115286 lentinan Drugs 0.000 claims abstract description 17
- 235000020183 skimmed milk Nutrition 0.000 claims abstract description 16
- 235000015112 vegetable and seed oil Nutrition 0.000 claims abstract description 10
- 239000008158 vegetable oil Substances 0.000 claims abstract description 10
- 239000005862 Whey Substances 0.000 claims abstract description 8
- 102000007544 Whey Proteins Human genes 0.000 claims abstract description 8
- 108010046377 Whey Proteins Proteins 0.000 claims abstract description 8
- 150000001875 compounds Chemical class 0.000 claims description 12
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 8
- 241000206575 Chondrus crispus Species 0.000 claims description 6
- 235000020247 cow milk Nutrition 0.000 claims description 6
- 150000003346 selenoethers Chemical class 0.000 claims description 6
- 235000012907 honey Nutrition 0.000 claims description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 4
- 229910052791 calcium Inorganic materials 0.000 claims description 4
- 239000011575 calcium Substances 0.000 claims description 4
- 229910052742 iron Inorganic materials 0.000 claims description 4
- 239000011701 zinc Substances 0.000 claims description 4
- 229910052725 zinc Inorganic materials 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 abstract description 37
- 235000013336 milk Nutrition 0.000 abstract description 19
- 239000008267 milk Substances 0.000 abstract description 19
- 210000004080 milk Anatomy 0.000 abstract description 19
- 201000011510 cancer Diseases 0.000 abstract description 17
- 235000016709 nutrition Nutrition 0.000 abstract description 12
- 230000035764 nutrition Effects 0.000 abstract description 9
- 239000000047 product Substances 0.000 abstract description 8
- 239000000203 mixture Substances 0.000 abstract description 6
- 201000010099 disease Diseases 0.000 abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 150000004676 glycans Chemical class 0.000 abstract description 5
- 229920001282 polysaccharide Polymers 0.000 abstract description 5
- 239000005017 polysaccharide Substances 0.000 abstract description 5
- 238000001959 radiotherapy Methods 0.000 abstract description 4
- 238000006243 chemical reaction Methods 0.000 abstract description 3
- 238000002512 chemotherapy Methods 0.000 abstract description 3
- 238000002360 preparation method Methods 0.000 abstract description 3
- 238000012545 processing Methods 0.000 abstract description 3
- 206010047700 Vomiting Diseases 0.000 abstract description 2
- 230000002496 gastric effect Effects 0.000 abstract description 2
- 235000003715 nutritional status Nutrition 0.000 abstract description 2
- 230000008673 vomiting Effects 0.000 abstract description 2
- 229920001525 carrageenan Polymers 0.000 abstract 2
- 229940113118 carrageenan Drugs 0.000 abstract 2
- 235000010418 carrageenan Nutrition 0.000 abstract 2
- 239000000679 carrageenan Substances 0.000 abstract 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 abstract 2
- 206010025476 Malabsorption Diseases 0.000 abstract 1
- 206010028813 Nausea Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 208000022531 anorexia Diseases 0.000 abstract 1
- 206010061428 decreased appetite Diseases 0.000 abstract 1
- 235000018823 dietary intake Nutrition 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000008693 nausea Effects 0.000 abstract 1
- 239000013589 supplement Substances 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 239000003814 drug Substances 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 9
- 235000015097 nutrients Nutrition 0.000 description 9
- 230000008569 process Effects 0.000 description 8
- 229940091258 selenium supplement Drugs 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 7
- 229910052711 selenium Inorganic materials 0.000 description 7
- 239000011669 selenium Substances 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 6
- 238000004659 sterilization and disinfection Methods 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000001954 sterilising effect Effects 0.000 description 5
- 210000001541 thymus gland Anatomy 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 238000012449 Kunming mouse Methods 0.000 description 4
- 240000002853 Nelumbo nucifera Species 0.000 description 4
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 4
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 208000002720 Malnutrition Diseases 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 3
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 3
- 239000011648 beta-carotene Substances 0.000 description 3
- 235000013734 beta-carotene Nutrition 0.000 description 3
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 3
- 229960002747 betacarotene Drugs 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 235000000824 malnutrition Nutrition 0.000 description 3
- 230000001071 malnutrition Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 208000015380 nutritional deficiency disease Diseases 0.000 description 3
- 239000011573 trace mineral Substances 0.000 description 3
- 235000013619 trace mineral Nutrition 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 3
- 206010003445 Ascites Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000002924 anti-infective effect Effects 0.000 description 2
- 230000003035 anti-peroxidant effect Effects 0.000 description 2
- 230000000743 anti-peroxide Effects 0.000 description 2
- 230000002567 autonomic effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000000973 chemotherapeutic effect Effects 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000003862 health status Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- -1 pachymaran Chemical class 0.000 description 2
- 230000000242 pagocytic effect Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 235000008476 powdered milk Nutrition 0.000 description 2
- 238000003672 processing method Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 206010020674 Hypermetabolism Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000005238 degreasing Methods 0.000 description 1
- 230000035617 depilation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000003194 forelimb Anatomy 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 230000000091 immunopotentiator Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 235000020185 raw untreated milk Nutrition 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
新型功能性奶粉的配制方法。本发明属于工业法加工含有各种有效活性成分的奶粉的制作方法。癌症本身是一种消耗性疾病,加之放、化疗所引起的一些胃肠道反应(恶心、呕吐、厌食及肠吸收不良等)使患者营养摄入不足,导致营养状态低下,所以补充合理的营养有利于病情的好转。本产品其组成包括:鲜牛乳、脱脂乳粉、乳清粉、植物油、香菇多糖、茯苓多糖、硒化卡拉胶、鲜牛乳的重量份数为65.5、脱脂乳粉的重量份数为10.6、植物油的重量份数为2.8、香菇多糖的重量份数为0.2、茯苓多糖的重量份数为0.4、硒化卡拉胶的重量份数为0.05、乳清粉的重量份数为10。本产品是一种功能性食用奶粉。
Description
技术领域:
本发明属于工业法加工含有各种有效活性成分的奶粉的制作方法。
背景技术:
癌症本身是一种消耗性疾病,加之放、化疗所引起的一些胃肠道反应(恶心、呕吐、厌食及肠吸收不良等)使之营养摄入不足,导致营养状态低下,进而不利于放化疗的顺利进行。据调查,有40%~80%的癌症患者存在不同程度的营养不良,因此应重视为癌症患者提供必要的营养支持。恶性肿瘤患者的营养主要是靠增加进食以提高其免疫功能及抗氧化能力,调整其它器官功能,增加人体抵抗力以达到延长生存期和提高生存质量的目的,其为提高肿瘤治疗疗效提供了一种新希望。
癌症患者所需热量一般为104.5~125.4KJ/kg/d,所需蛋白质为1~2g/kg/d。若患者营养状况良好,只需维持患者的营养平衡,同时指导患者合理膳食,多吃全谷类、豆类、蔬菜和水果以满足机体的生理需要;若患者有体重减轻,则可能有营养不良的危险或已出现营养不良,尤其对不能自主摄入足够食物者,此时应根据患者的饮食习惯和营养状况制定完善的饮食计划及促进食欲的方案以保证营养平衡,防止加重营养不良。造成癌症患者免疫功能障碍的重要因素是营养不良,而非肿瘤本身。肿瘤生长对宿主的营养状况有极大的影响,多数肿瘤患者都有严重的营养问题,恶性肿瘤的治疗加重患者的营养损害。手术前后禁食、术后基础耗能的增加、放射治疗、化学治疗的副作用以及肿瘤本身代谢亢进、营养物质的需求量增多,致使肿瘤患者发生不同程度的营养障碍,营养障碍又常常增加手术的危险性,影响各种治疗的耐受性,延长恢复过程。
随着社会发展和人们健康意识的增强,在预防和治疗各种疾病的过程中,使用辅助和替代药物近年来比较常见。人们往往是因为害怕抗癌药物的不良反应而不愿意使用处方药物,于是转而求助膳食补充剂或植物药治疗其 疾病。在临床工作中,癌症患者更愿意选择使用传统药物或替代药物治疗疾病。调查表明,64%~70%的癌症患者使用替代药物;同时有50%的患者并未告诉医生他们使用了替代疗法。临床当中常见的替代疗法包括使用植物药、维生素和膳食产品等。这些产品的功能主要来自于其具有抗过氧化的特性。有关资料显示,富含抗过氧化物的水果和蔬菜可降低人体癌症发生几率。而抗过氧化剂补充剂是含量更高的抗过氧化物制剂,有报道显示,它可降低机体某些组织癌变的风险。特别是维生素E和硒补充剂,可明显减少前列腺癌、结肠癌的发生。
应用中医中药和营养素结合,是达到提高肿瘤治疗疗效的重要手段之一。中药中含有多糖类成分,能在抗肿瘤、抗炎症、提高免疫力等方面发挥作用。若将其浓度控制在一定范围内,则不会对辐射产生一些生物学效应方面的影响,不会相互拮抗而影响放疗疗效,甚至还可使细胞中活性氧增高,促进肿瘤细胞受损凋亡。若结合营养素如β-胡萝卜素、维生素C、维生素E和微量元素硒等还可帮助纠正营养不良。乳粉为营养成分丰富、均衡的优质食品。
发明内容:
本发明以乳粉作为食品载体,通过添加茯苓多糖、香菇多糖等中药多糖与奶粉中的营养素结合,生产出适合癌症患者食用的功能性奶粉。
上述的目的通过以下的技术方案实现:
新型功能性奶粉的配制方法,其组成包括:鲜牛乳、脱脂乳粉、乳清粉、植物油、香菇多糖、茯苓多糖、硒化卡拉胶,所述的鲜牛乳的重量份数为65.5、所述的脱脂乳粉的重量份数为10.6、所述的植物油的重量份数为2.8、所述的香菇多糖的重量份数为0.2、所述的茯苓多糖的重量份数为0.4、所述的硒化卡拉胶的重量份数为0.05、所述的乳清粉的重量份数为10。
所述的一种新型功能性奶粉的配制方法,其中还加入了蜂蜜、低聚果糖、钙、铁、锌、β-胡萝卜素、VE、VC等辅料,所述的蜂蜜的重量份数为10.4、所述的低聚果糖的重量份数为0.7、所述的钙的重量份数为0.007、所述的铁 的重量份数为0.00009~0.00014、所述的锌的重量份数为0.00009~0.00012、所述的β-胡萝卜素的重量份数为0.041、所述的VE的重量份数为0.0006~0.00062、所述的VC的重量份数为0.00095~0.00098。
所述的一种新型功能性奶粉的配制方法,所述的配备过程确定热能设定范围为1.5~1.9MJ/100g,蛋白质、脂肪和碳水化合物的含量范围为19~21%、23~25%和45~50%。
这个技术方案有以下有益效果:
1.本品所含的茯苓多糖对生长迟缓型的移植肿瘤可达到强烈的抑制作用,对正常细胞辐射防护作用的同时基本不会影响放疗的效果,使巨噬细胞的吞噬率和吞噬指数明显增加,能增强T淋巴细胞的细胞毒性作用,即增强细胞反应,并因此而激活机体对肿瘤的免疫监督系统。
2.本品中所含的香菇多糖具有免疫调节活性及抗感染、抗肿瘤作用。与其它抗肿瘤药物相比,香菇多糖几乎无任何副作用,是目前已知最强免疫增强剂之一。香菇多糖的抗肿瘤、抗感染作用是通过提高机体的免疫功能来实现的。香菇多糖对正常机体并无免疫促进作用,但对机体免疫功能下降或感染疾病患上癌症后而造成人体免疫系统紊乱患者,能有效调节多种细胞免疫因子,起到调节免疫系统平衡作用。其免疫作用特点在于识别脾及肝脏中抗原的巨噬细胞,促进淋巴细胞活化因子的产生,释放各种辅助性T细胞因子,诱导或增强宿主腹腔巨噬细胞吞噬作用,恢复或刺激辅助性T细胞的功能,同时促进免疫球蛋白形成的核酸蛋白合成,提高机体的免疫功能。许多学者研究了香菇多糖对临床癌症患者免疫状态的影响,证实香菇多糖与化疗合用可提高化疗疗效,增加淋巴细胞转化率、NK细胞活性。
3.本发明所含的硒酸酯多糖这种有机态结构极为有效地提高了硒的生物可利用度及其作为生物必需微量元素的生理功能,它含有人体所必需的有机硒元素,且毒性和副作用比无机硒大大降低,因此它是一种安全、有效、健康的硒源营养强化剂。硒是人体内谷胱甘肽过氧化物酶的活性成分,该酶具有清除代谢过程中产生的自由基和过氧化物的作用,有调节氧化还原反应 速度,强化某些酶系统的活性及调节维生素A、C、E、K在体内吸收和消耗的功能,对汞、镉等重金属有解毒作用,硒具有激活机体免疫系统的功能,可提高机体免疫力,增强对疾病的抵抗能力,具有促进生长,保护视力和视器官健全的功能,抗肿瘤作用。
4.本发明所含的乳脂肪含有一些具有抗癌特性的成分,其中共轭亚油酸和神经鞘磷脂具有更重要的抗癌特性。
新型功能性奶粉的配制方法对荷H22小鼠的体内抑瘤实验
(1)荷H22小鼠模型的建立
断颈处死腹腔保种H22细胞的昆明小鼠,于消毒酒精中浸泡约5mins,无菌条件下剪开小鼠腹部皮肤暴露腹膜,以镊子挑起腹膜并剪开一小口,取吸管吸取腹腔中含H22肿瘤细胞的腹水于无菌烧杯中。以生理盐水稀释细胞,镜下计数细胞数约为106cells/ml。混匀细胞后用一次性注射器在小鼠右侧前肢腋下皮下注射0.2ml细胞悬液,接种2h后称重分组,常温下正常饲养。
(2)实验分组及给药方式(如表2-9所示)
昆明小鼠,体重18±2g,雌雄各半。
表2-9实验分组
Table2-9Grouping of Experiment
所有小鼠在同等条件下饲养,任期自由生长,共给药10天,第11天处死。
(3)对荷瘤小鼠体重及健康状况的影响
各组小鼠接种后第2d起,隔日称重一次;每日观察小鼠的健康状况及肿瘤形成情况。
(4)荷瘤小鼠肝功能检测
停药后次日处死小鼠,采用断头取血方式取小鼠血,分离血清,标本以全自动生化分析仪检测。
(5)抑瘤作用检测
尸解观察小鼠腹水形成及肿瘤的转移情况,剥瘤称重,测定抑瘤率(%),抑瘤率计算公式如下:
(6)肿瘤组织病理形态学观察
各实验组小鼠肿瘤组织解剖后观察大体形态,进行病理组织切片后HE染色观察。
对荷瘤小鼠脏体比的影响
(1)实验动物造模及分组处理方法参见以上叙述。
(2)胸腺指数和脾脏指数计算
各组小鼠停药后次日处死,完整取出脾脏和胸腺后称重,计算胸腺指数和脾脏指数。
胸腺(脾)指数=胸腺(脾)重量(mg)/体重(kg)
荷瘤小鼠生命延长率实验
(1)实验动物造模及分组处理方法参见以上叙述。
连续给药10天后停药,记录各组小鼠生存天数,到第25天仍存活者按25天记。
(2)小鼠生命延长率(ILS)计算
ILS=(T/C—1)×100%
T:给药组小鼠平均存活天数C:空白对照组小鼠平均存活天数
新型功能性奶粉的配制方法高、中、低剂量组对荷H22昆明小鼠模型的生命延率分别为38.52%、22.22%、22.96%,通过生存时间分析来看,新型功能性奶粉的配制方法组生存时间均明显高于空白对照组及普通奶粉组(p<0.01);与CTX组比较,新型功能性奶粉的配制方法高剂量组生命明显延长(p<0.01)。
本实验以昆明小鼠荷H22肝癌移植瘤模型为研究对象,设定三个浓度的新型功能性奶粉的配制方法(高、中、低)给予小鼠灌胃,观察小鼠生长情 况,并对肿瘤抑制作用及生命延长率(ILS)进行分析,同时以生理盐水为空白对照组,以环磷酰胺为阳性对照。结果表明:本产品可改善荷瘤小鼠体制,缓解阳性药物对小鼠造成的脱毛、精神萎靡等不良影响;且新型功能性奶粉的配制方法组小鼠体重增加明显大于环磷酰胺(CTX)组及空白对照组(p<0.01),生存时间有所延长,ILS大于22%;但产品对H22实体瘤的抑制作用不是十分明显,抑制率小于30%。
本实验研究得到一种适合癌症患者食用的功能性奶粉。此奶粉可改善癌症患者机体状况,为患者提供营养支持,有效延长患者生存时间。
附图说明:
附图1为本发明工艺的流程图。
本发明的具体实施方式:
实施例1:
此种适合肿瘤病人食用的奶粉的加工工艺及工艺流程以普通奶粉的工艺流程和工艺条件为基础,这样可以尽可能地减少设备方面的开支,降低成本。鲜牛乳、脱脂乳粉、乳清粉、植物油、香菇多糖、茯苓多糖、硒化卡拉胶,所述的鲜牛乳的重量份数为65.5、所述的脱脂乳粉的重量份数为10.6、所述的植物油的重量份数为2.8、所述的香菇多糖的重量份数为0.2、所述的茯苓多糖的重量份数为0.4、所述的硒化卡拉胶的重量份数为0.05、所述的乳清粉的重量份数为10。
采取工艺流程如下:
(1)原料乳的验收酸度≤10,干物质含量≥11.5,脂肪含量于≥3.0,蛋白质≥2.9%。
(2)预处理及标准化鲜乳要经过过滤,除去乳中的杂质,并进行标准化。
(3)配料先按配料表中给出的各种原料的用量准备各种原料。脱脂奶粉加水溶解温度50℃,水:脱脂粉按4:1溶解,然后再加入植物油混匀,溶解的顺序为:鲜奶→脱脂奶粉→蜂蜜→低聚果糖→植物油→三种多糖→微 量元素→维生素
(4)均质二段均质,均质压力180~200Mpa。
(5)杀菌杀菌温度85℃(83~88℃)
(6)浓缩采用双效降膜真空浓缩蒸发器。
一效真空度-0.05Mpa 一效蒸发温度73℃(70~76℃)
二效真空度-0.10Mpa 二效蒸发温度50℃(48~52℃)
(7)喷雾干燥喷雾干燥的工艺条件是:喷雾压力10~12Mpa;排风温度75℃;喷雾的孔眼直径3~5mm;进风温度145~150℃。
(8)冷却筛粉
(9)称量在经过灭菌的环境中进行。
(10)包装
实施例2:
实施里1所述的奶粉中的基础配方的选择:
脱脂乳与全脂乳配方的选择
将相同蛋白质浓度的全脂乳与脱脂乳对SGC-7901及KYSE-510两种细胞作用,分析脂肪对以上两种癌细胞的影响,确定新型功能性奶粉的配制方法是采用全脂或脱脂配方。所用全脂乳粉的蛋白含量为24%,脱脂乳粉的蛋白含量为35%。
(1)肿瘤细胞的复苏
①从液氮罐中取出保存有SGC-7901及KYSE-510细胞株的冻存管,迅速置于37℃的水浴箱中,并反复摇动,直至冻存管中无固态物质,取出置于超净台中。
②用70%乙醇仔细擦净冻存管的管口后开盖,用1000μl微量移液器吸净管中液体,转移至10ml离心管中。
③补加8ml RPMI1640培养基,1000rpm离心5min,弃上清。
④加入4ml配制好的含10%FBS的RPMI1640培养基,轻轻吹打混匀后置入50ml细胞培养瓶中,转入37℃、5%CO2培养箱中培养过夜。
⑤次日进行完全换液后继续培养。
(2)肿瘤细胞的培养与传代
①每日用倒置显微镜检查细胞,如发现污染或细胞碎裂,必须丢弃。
②肉眼观察培养液颜色,如果颜色由红色转为黄色,需要及时更换培养液。
③当细胞在培养瓶底长至80%满时,需进行传代。
(3)MTT法测定脱脂乳及全脂乳对肿瘤细胞的作用
①取处于指数生长期的细胞,用含有10%胎牛血清的培养液稀释成5×104个/ml。
②取3块灭菌96孔板,每孔中加入100μl细胞悬液,置于37℃、5%CO2孵箱中培养24h。
③将杀菌处理过的全脂乳及脱脂乳用按比例稀释,每孔中加100μl稀释液,设三复孔,使孔中终蛋白浓度为21μg/ml、42μg/ml、84μg/ml、168μg/ml的4个梯度。对照孔中加入100μl RPMI1640培养液。
④置于37℃、5%CO2孵箱中培养。分别于24h、48h、72h各取出一个96孔板进行MTT实验。
⑤每孔中加入5mg/ml MTT溶液10μl,置于37℃、5%CO2孵箱中孵育4h。
⑥吸出上清,加入100μl DMSO,用摇床摇匀。
⑦测定OD490值。
⑧计算细胞生长抑制率:抑制率%=(1-(实验组A490/空白对照组A490))×100%
各功能因子用量的确定
以乳粉中将添加的香菇多糖、茯苓多糖、硒酸酯多糖三种功能因子为因素,做L9(33)正交实验,根据对SGC-7901及KYSE-510两种肿瘤细胞的体外抑制率实验(MTT实验方法同2.3.1.1(3))确定各种多糖最佳配比添加方式。三种功能因子配比的因素水平表如表2-1所示:
表2-1功能因子配比因素水平表
Claims (1)
1.一种新型功能性奶粉的配制方法,其原料组成为:鲜牛乳、脱脂乳粉、乳清粉、植物油、香菇多糖、茯苓多糖、硒化卡拉胶、蜂蜜、低聚果糖、钙、铁、锌、β胡萝卜素、VE、VC,其特征是:所述的鲜牛乳的重量份数为65.5,所述的脱脂乳粉的重量份数为10.6,所述的植物油的重量份数为2.8,所述的香菇多糖的重量份数为0.2,所述的茯苓多糖的重量份数为0.4,所述的硒化卡拉胶的重量份数为0.05,所述的乳清粉的重量份数为10,所述的蜂蜜的重量份数为10.4,所述的低聚果糖的重量份数为0.7,所述的钙的重量份数为0.007,所述的铁的重量份数为0.00009-0.00014,所述的锌的重量份数为0.00009-0.00012,所述的β胡萝卜素的重量份数为0.041,所述的VE的重量份数为0.0006-0.00062,所述的VC的重量份数为0.00095-0.00098。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2007100723227A CN101317605B (zh) | 2007-06-06 | 2007-06-06 | 新型功能性奶粉的配制方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2007100723227A CN101317605B (zh) | 2007-06-06 | 2007-06-06 | 新型功能性奶粉的配制方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101317605A CN101317605A (zh) | 2008-12-10 |
CN101317605B true CN101317605B (zh) | 2011-02-16 |
Family
ID=40178084
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2007100723227A Expired - Fee Related CN101317605B (zh) | 2007-06-06 | 2007-06-06 | 新型功能性奶粉的配制方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101317605B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104542983A (zh) * | 2014-12-15 | 2015-04-29 | 广东高鑫科技股份有限公司 | 癌症病人辅助治疗配方奶粉及其制备方法 |
CN105211857B (zh) * | 2015-09-30 | 2018-03-13 | 广州金酮医疗科技有限公司 | 一种营养组合物及其用途 |
CN110122572B (zh) * | 2019-05-30 | 2022-06-24 | 重庆工商大学 | 一种基于富铬香菇菌丝的保护视力的富铬功能性奶粉 |
-
2007
- 2007-06-06 CN CN2007100723227A patent/CN101317605B/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN101317605A (zh) | 2008-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104083468B (zh) | 一种治疗男性少精弱精、提高精子质量的药物 | |
CN104826087B (zh) | 复合辣木多肽及其制备方法和应用 | |
CN107319525A (zh) | 一种减肥减脂专用型临床营养配方及其制备方法 | |
CN109156817A (zh) | 一种无乳糖婴儿配方食品及其制备方法 | |
CN104432037B (zh) | 抗氧化的保健营养组合物及其制备方法与应用 | |
BRPI0709083A2 (pt) | composições que compreendem porphyra e métodos de preparação e utilização destas | |
CN102511861A (zh) | 一种添加低聚糖的红枣浓浆 | |
CN101530466B (zh) | 一种含有牛至油和维生素的纳米药物 | |
CN106858595A (zh) | 一种烧伤专用型临床营养配方及其制备方法 | |
CN105768108A (zh) | 一种适用于肿瘤患者服用的特膳食品 | |
CN102511864A (zh) | 一种红枣浓浆 | |
CN101317605B (zh) | 新型功能性奶粉的配制方法 | |
Saparova et al. | The effectiveness of phytobiotic additives in the diet of sheep | |
CN100551267C (zh) | 富硒锌保健食品及其制备方法 | |
WO2016141775A1 (zh) | 吉林人参低聚肽在制备抗疲劳的食品或保健食品中的用途 | |
CN110754656A (zh) | 一种淋巴肿瘤功能专用型临床营养配方及其制备方法 | |
RU2521369C1 (ru) | Препарат для стимуляции обменных процессов, профилактики и лечения желудочно-кишечных заболеваний телят в ранний постнатальный период | |
CN103988912A (zh) | 一种富硒黑奶茶的制作方法 | |
CN103621871B (zh) | 一种复合氨基酸保健品及其制备方法 | |
CN106923334A (zh) | 一种虾青素软胶囊配方及其制备方法 | |
CN102987501B (zh) | 用蛹虫草、茧提取物制备保健食(疗)品之营养(液)饮料及冲剂的方法 | |
CN101317665A (zh) | 一种维持人体健康长寿碱性高能剂 | |
CN1961747A (zh) | 一种富硒锌保健食品及其制备方法 | |
CN104432061B (zh) | 生物胚胎细胞营养素 | |
CN107136490A (zh) | 一种肽虫草保健品 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110216 Termination date: 20110606 |